Safety and efficacy of liquid nitrogen spray cryotherapy in Barrett’s neoplasia – a comprehensive review and meta-analysis

Abstract

Background and study aims Barrett’s esophagus (BE) is a precursor condition to esophageal adenocarcinoma (EAC), resulting in transformation of the squamous epithelium of distal esophagus to columnar-lined epithelium with intestinal metaplasia (IM). Liquid nitrogen spray cryotherapy (LNSC) is a non-contact method of BE eradication and has been used both as primary and salvage therapy. We conducted a systematic review and meta-analysis to assess the safety and efficacy of LNSC.

Methods We searched multiple databases from inception through December 2021 to identify studies on use of LNSC for Barrett’s neoplasia. Pooled estimates were calculated using random-effects model and results were expressed in terms of pooled proportions with relevant 95 % confidence intervals (CIs) of complete eradication (CE) of dysplasia(D), high grade dysplasia (HGD) and IM.

Results Fourteen studies with 707 patients were included in our final analysis. Overall pooled rates of CE-D, CE-HGD and CE-IM were 80.8 % (CI 77.4–83.8; I² 62), 90.3 % (CI 85.2–93.7; I² 33) and 55.8 % (CI 51.7–59.8; I² 73) with follow up ranging from 4.25 months to 69.7 months. In patients with follow up beyond 24 months, the rates of CE-D and CE-IM were 83.6 % (CI 77.6–88.2; I² 60) and 54.7 % (CI 47.6–61.6; I² 81). Among LNSC naïve patients with prior history of endoscopic resection, the rates were 79.9 % (CI 73.3–85.2; I² 50) and 67.1 % (CI 59.5–73.8; I² 0). Pooled rate of therapeutic failures, defined as lack of response to LNSC therapy, was 23.6 % (CI 19.4–28.3; I² 73). Post LNSC strictures and perforation pooled rates were 4 % and 0.8 %, respectively, which are similar to those previously reported for RFA.

Conclusions Our analysis suggests that liquid nitrogen spray cryotherapy is an acceptable treatment for BE in both ablation naïve and experienced patients.

Publication History

Received: 07 February 2022

Accepted after revision: 20 July 2022

Accepted Manuscript online:
21 July 2022

Article published online:
15 November 2022

• References

• 1 Rastogi A, Puli S, El-Serag HB. et al. Incidence of esophageal adenocarcinoma in patients with Barrettʼs esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 2008; 67: 394-398
• 2 Orloff M, Peterson C, He X. et al. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAMA 2011; 306: 410-419
• 3 Schoofs N, Bisschops R, Prenen H. Progression of Barrettʼs esophagus toward esophageal adenocarcinoma: an overview. Ann Gastroenterol 2017; 30: 1-6
• 4 Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA 2013; 310: 627-636
• 5 Shaheen NJ, Falk GW, Iyer PG. et al. ACG Clinical Guideline: Diagnosis and Management of Barrettʼs Esophagus. Am J Gastroenterol 2016; 111: 30-50
• 6 Phoa KN, van Vilsteren FG, Weusten BL. et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA 2014; 311: 1209-1217
• 7 Prasad GA, Wang KK, Buttar NS. et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrettʼs esophagus. Gastroenterology 2007; 132: 1226-1233
• 8 Anders M, Bähr C, El-Masry MA. et al. Long-term recurrence of neoplasia and Barrettʼs epithelium after complete endoscopic resection. Gut 2014; 63: 1535-1543
• 9 Guo HM, Zhang XQ, Chen M. et al. Endoscopic submucosal dissection vs endoscopic mucosal resection for superficial esophageal cancer. World J Gastroenterol 2014; 20: 5540-5547
• 10 Peter S, Mönkemüller K. Ablative endoscopic therapies for Barrettʼs esophagus-related neoplasia. Gastroenterol Clin North Am 2015; 44: 337-353
• 11 Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrettʼs Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1245-1255
• 12 Johnston CM, Schoenfeld LP, Mysore JV. et al. Endoscopic spray cryotherapy: a new technique for mucosal ablation in the esophagus. Gastrointest Endosc 1999; 50: 86-92
• 13 Pasricha PJ, Hill S, Wadwa KS. et al. Endoscopic cryotherapy: experimental results and first clinical use. Gastrointest Endosc 1999; 49: 627-631
• 14 Friedland S, Triadafilopoulos G. A novel device for ablation of abnormal esophageal mucosa (with video). Gastrointest Endosc 2011; 74: 182-188
• 15 Muguruma N, Marcon NE. Technique and emerging role of cryotherapy. Techniq Gastrointest Endosc 2010; 12: 44-48
• 16 Spiceland CM, Elmunzer BJ, Paros S. et al. Salvage cryotherapy in patients undergoing endoscopic eradication therapy for complicated Barrettʼs esophagus. Endosc Int Open 2019; 7: E904-E911
• 17 Visrodia K, Zakko L, Singh S. et al. Cryotherapy for persistent Barrettʼs esophagus after radiofrequency ablation: a systematic review and meta-analysis. Gastrointest Endosc 2018; 87: 1396-1404.e1391
• 18 Tariq R, Enslin S, Hayat M. et al. Efficacy of cryotherapy as a primary endoscopic ablation modality for dysplastic Barrettʼs esophagus and early esophageal neoplasia: a systematic review and meta-analysis. Cancer Control 2020; 27
• 19 Mohan BP, Krishnamoorthi R, Ponnada S. et al. Liquid nitrogen spray cryotherapy in treatment of Barrettʼs esophagus, where do we stand? a systematic review and meta-analysis. Dis Esophagus 2019; 32: doy130
• 20 Stroup DF, Berlin JA, Morton SC. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012
• 21 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
• 22 Sutton AJAK, Jones DR. et al. Methods for meta-analysis in medical research. New York: J. Wiley; 2000
• 23 Mohan BP, Adler DG. Heterogeneity in systematic review and meta-analysis: how to read between the numbers. Gastrointest Endosc 2019; 89: 902-903
• 24 Higgins J, Thompson SG, Spiegelhalter DJ. A re‐evaluation of random‐effects meta‐analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society) 2009; 172: 137-159
• 25 Higgins JP, Thompson SG, Deeks JJ. et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
• 26 Duval S, Tweedie R. Trim and fill: a simple funnel-plot–based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455-463
• 27 Dumot JA, Vargo II JJ, Falk GW. et al. An open-label, prospective trial of cryospray ablation for Barrettʼs esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc 2009; 70: 635-644
• 28 Shaheen NJ, Greenwald BD, Peery AF. et al. Safety and efficacy of endoscopic spray cryotherapy for Barrettʼs esophagus with high-grade dysplasia. Gastrointest Endosc 2010; 71: 680-685
• 29 Halsey KD, Chang JW, Waldt A. et al. Recurrent disease following endoscopic ablation of Barrettʼs high-grade dysplasia with spray cryotherapy. Endoscopy 2011; 43: 844-848
• 30 Sengupta N, Ketwaroo GA, Bak DM. et al. Salvage cryotherapy after failed radiofrequency ablation for Barrettʼs esophagus-related dysplasia is safe and effective. Gastrointest Endosc 2015; 82: 443-448
• 31 Suchniak-Mussari K, Dye CE, Moyer MT. et al. Efficacy and safety of liquid nitrogen cryotherapy for treatment of Barrett’s esophagus. World J Gastrointest Endosc 2017; 9: 480
• 32 Ramay FH, Cui Q, Greenwald BD. Outcomes after liquid nitrogen spray cryotherapy in Barrettʼs esophagus–associated high-grade dysplasia and intramucosal adenocarcinoma: 5-year follow-up. Gastrointest Endosc 2017; 86: 626-632
• 33 Trindade AJ, Inamdar S, Kothari S. et al. Feasibility of liquid nitrogen cryotherapy after failed radiofrequency ablation for Barrettʼs esophagus. Dig Endosc 2017; 29: 680-685
• 34 Trindade AJ, Pleskow DK, Sengupta N. et al. Efficacy of liquid nitrogen cryotherapy for Barrettʼs esophagus after endoscopic resection of intramucosal cancer: A multicenter study. J Gastroenterol Hepatol 2018; 33: 461-465
• 35 Thota PN, Arora Z, Dumot JA. et al. Cryotherapy and radiofrequency ablation for eradication of Barrett’s esophagus with dysplasia or intramucosal cancer. Digest Dis Sci 2018; 63: 1311-1319
• 36 Kaul V, Bittner K, Ullah A. et al. Liquid nitrogen spray cryotherapy-based multimodal endoscopic management of dysplastic Barrett’s esophagus and early esophageal neoplasia: retrospective review and long-term follow-up at an academic tertiary care referral center. Dis Esophagus 2020; 33: doz095
• 37 Fasullo M, Shah T, Patel M. et al. Outcomes of radiofrequency ablation compared to liquid nitrogen spray cryotherapy for the eradication of dysplasia in Barrett’s esophagus. Digest Dis Sci 2022; 67: 2320-2326
• 38 Alshelleh M, Raphael KL, Inamdar S. et al. Cryoballoon and cryospray ablation therapies are equivalent for eradication of Barrettʼs esophagus. Techniq Innovat Gastrointest Endosc 2021; 23: 110-112
• 39 Greenwald BD, Dumot JA, Horwhat JD. et al. Safety, tolerability, and efficacy of endoscopic low-pressure liquid nitrogen spray cryotherapy in the esophagus. Dis Esophagus 2010; 23: 13-19
• 40 Ghorbani S, Tsai FC, Greenwald BD. et al. Safety and efficacy of endoscopic spray cryotherapy for Barrettʼs dysplasia: results of the National Cryospray Registry. Dis Esophagus 2016; 29: 241-247
• 41 Qumseya BJ, Wani S, Desai M. et al. Adverse events after radiofrequency ablation in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 1086-1095 .e1086
• 42 Fitzgerald RC, di Pietro M, Ragunath K. et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrettʼs oesophagus. Gut 2014; 63: 7-42
• 43 Spechler SJ, Sharma P, Souza RF. et al. American Gastroenterological Association medical position statement on the management of Barrettʼs esophagus. Gastroenterology 2011; 140: 1084-1091
• 44 Cotton CC, Wolf WA, Overholt BF. et al. Late recurrence of Barrettʼs esophagus after complete eradication of intestinal metaplasia is rare: final report from Ablation in Intestinal Metaplasia Containing Dysplasia Trial. Gastroenterology 2017; 153: 681-688.e682
• 45 Vaccaro BJ, Gonzalez S, Poneros JM. et al. Detection of intestinal metaplasia after successful eradication of Barrettʼs esophagus with radiofrequency ablation. Dig Dis Sci 2011; 56: 1996-2000
• 46 Wolf WA, Pasricha S, Cotton C. et al. Incidence of esophageal adenocarcinoma and causes of mortality after radiofrequency ablation of Barrettʼs esophagus. Gastroenterology 2015; 149: 1752-1761.e1751
• 47 van Munster S, Nieuwenhuis E, Weusten BLAM. et al. Long-term outcomes after endoscopic treatment for Barrettʼs neoplasia with radiofrequency ablation ± endoscopic resection: results from the national Dutch database in a 10-year period. Gut 2021;
• 48 Spiceland CM, Elmunzer BJ, Paros S. et al. Salvage cryotherapy in patients undergoing endoscopic eradication therapy for complicated Barrett’s esophagus. Endosc Int Open 2019; 7: E904-E911
• 49 Othman MO, Lee JH, Wang K. AGA clinical practice update on the utility of endoscopic submucosal dissection in T1b esophageal cancer: expert review. Clin Gastroenterol Hepatol 2019; 17: 2161-2166